Role of systemic antibiotics in preventing epidermal growth factor receptor: Tyrosine kinase inhibitors-induced skin toxicities
Open Access
- 1 October 2017
- journal article
- review article
- Published by Elsevier in Asia-Pacific Journal of Oncology Nursing
- Vol. 4 (4) , 323-329
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a metaanalysisRadiology and Oncology, 2013
- Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?Archives of Dermatological Research, 2013
- Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and ManagementChemotherapy Research and Practice, 2012
- Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature ReviewThe Oncologist, 2012
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesSupportive Care in Cancer, 2011
- Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common CancersJournal of Oncology, 2009
- Tetracycline to prevent epidermal growth factor receptor inhibitor‐induced skin rashesCancer, 2008
- Dermatologic side effects associated with the epidermal growth factor receptor inhibitorsJournal of the American Academy of Dermatology, 2006
- Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitorsAnnals of Oncology, 2005
- Cutaneous side-effects of kinase inhibitors and blocking antibodiesThe Lancet Oncology, 2005